Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 308 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atorvastatin (Lipitor) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

NCT06567327
View directory record Official record
Conditions
Obesity
Interventions
Danuglipron, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol

NCT00529542
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Lipitor, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

NCT01525407
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Atorvastatin Calcium, Peripheral Blood Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Stanford, California • Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 24, 2026, 4:04 PM EDT
Enrolling by invitation Phase 2 Interventional

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

NCT05826912
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Atorvastatin Calcium, Minocycline Hydrochloride, Candesartan Cilexetil, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
San Francisco, California • Indianapolis, Indiana • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease

NCT01732718
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Nephropathy
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

NCT02659397
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ETC-1002, Atorvastatin, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Northridge, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 24, 2026, 4:04 PM EDT
Recruiting Phase 4 Interventional

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

NCT06632379
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Interventions
Atorvastatin 10 mg, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 24, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

NCT01130246
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
A-002, varespladib methyl, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
5,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 3 Interventional

Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia

NCT00134485
View directory record Official record
Conditions
Hypercholesterolemia, Familial, Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Lutz, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2007 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 4 Interventional

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

NCT00926614
View directory record Official record
Conditions
Hepatitis c
Interventions
pioglitazone (Actos), atorvastatin (Lipitor)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Cerebral and Peripheral Perfusion Pilot Study

NCT00751907
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

NCT02608697
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
CAT-2054, Placebo, Atorvastatin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
34
States / cities
Muscle Shoals, Alabama • Huntington Park, California • Lomita, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 24, 2026, 4:04 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

NCT06974084
View directory record Official record
Conditions
Long COVID
Interventions
Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin
Drug
Lead sponsor
HealthBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 24, 2026, 4:04 PM EDT
Withdrawn Phase 1Phase 2 Interventional

High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study

NCT03188978
View directory record Official record
Conditions
Primary Arteriovenous Fistula Failure
Interventions
Atorvastatin 40mg, Placebo
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

NCT00094172
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

NCT01138072
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2248761, Simvastatin, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

NCT01527045
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Aggressive Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

NCT00300430
View directory record Official record
Conditions
Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions
ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Sep 24, 2026, 4:04 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

MicroRNA Activation of LOX-1 Mechanisms in Endometriosis

NCT05331053
View directory record Official record
Conditions
Endometriosis
Interventions
Atorvastatin
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 24, 2026, 4:04 PM EDT
Completed No phase listed Observational

Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor

NCT01078285
View directory record Official record
Conditions
Medication Non-Adherence
Interventions
No Patient Counseling, Adherence Counseling
Behavioral
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Actual Use Trial of Atorvastatin Calcium 10 mg

NCT01964326
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin calcium 10 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
37
States / cities
Hoover, Alabama • McCalla, Alabama • Pinson, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962
View directory record Official record
Conditions
Hyperlipidemia
Interventions
AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 24, 2026, 4:04 PM EDT
Terminated Phase 4 Interventional Results available

Quality of Life in Patients With Statin-Associated Myopathy

NCT00850460
View directory record Official record
Conditions
Statin Adverse Reaction
Interventions
Statins, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 24, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional Results available

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

NCT02850081
View directory record Official record
Conditions
Carotid Artery Stenosis, Strokes
Interventions
Statin, Atorvastatin, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 24, 2026, 4:04 PM EDT